Ilias Triantafyllou

Statistics

Publications

Citations

272

H-Index

Active since

2010

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Celerion (United States)

Orlando Clinical Research Center

Ilias Triantafyllou is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in clinical pharmacology, pharmacology, and pharmacokinetics.

Publications per year

2010–2020

Publications

Discovery of a Novel Class of Orally Active Antifungal β-1,3- <scp>d</scp> -Glucan Synthase Inhibitors

Scott S. Walker, Yiming Xu, Ilias Triantafyllou et al. · Antimicrobial Agents and Chemotherapy · 2011 · 75 citations · Full text

Life Sciences, Microbiology, Pharmacology +17

Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study

Sauzanne Khalilieh, Ka Lai Yee, Rosa I. Sánchez et al. · Antimicrobial Agents and Chemotherapy · 2016 · 44 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function

Michelle Treitel, Thomas Marbury, Richard A. Preston et al. · Clinical Pharmacokinetics · 2012 · 42 citations

Pharmacy, Pharmacokinetics, Pharmacology +10

Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects

Ka Lai Yee, Rosa I. Sánchez, Patrice Auger et al. · Antimicrobial Agents and Chemotherapy · 2016 · 26 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics

Sauzanne Khalilieh, Ka Lai Yee, Rachael Liu et al. · The Journal of Clinical Pharmacology · 2016 · 22 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

1–5 of 10